Kaken Pharmaceutical Co., Ltd. (4521.T)
Tokyo · JPY · Healthcare · Drug Manufacturers - Specialty & Generic
¥3,790 (-1.81%) as of
Key statistics
- Market cap
- 143.52B
- P/E (TTM)
- 66.84
- Forward P/E
- 39.32
- EPS (TTM)
- 56.70
- Dividend yield
- 4.95%
- 52-week range
- 3,540.00 – 4,445.00
- Revenue (TTM)
- 88.16B
- Profit margin
- 11.70%
- Analyst target
- ¥4,575
- Volume
- 52.20k
About Kaken Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations; Seladelpar that is in phase III clinical trial for primary biliary cholangitis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Tokyo, Japan
- Employees
- 1,114
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.